4 chapters across the catalog
President Donald Trump signs an executive order to reschedule marijuana from Schedule I to Schedule III, citing its legitimate medical uses for chronic pain, cancer, and seizure disorders. Trump is joined by Robert F. Kennedy Jr. and Dr. Mehmet Oz for the announcement, emphasizing that this is not a move toward full recreational legalization. The President warns against the dangers of unregulated, fentanyl-laced drugs while acknowledging the high public support for medical reclassification.
Methylene Blue Science, Cellular Health and Glucose Uptake
The science behind Methylene Blue is explored, focusing on its ability to turn superoxide into water and heal damaged mitochondrial pathways. The compound is noted for increasing glucose uptake in the brain, which enhances cognitive focus similar to the mental energy used by chess masters. Personal anecdotes describe the substance relieving chronic back pain and lifting long-term brain fog.
Maha Commission, Robert F. Kennedy Jr, Pain MD
The Maha Commission's report on childhood chronic disease is highlighted, with praise for Robert F. Kennedy Jr.'s work in exposing health crises. An advertisement for "Pain MD" follows, describing it as a natural pain reliever derived from Central and South American herbs with high user ratings.
Stanford Psilocybin Study, MKUltra Parallels
Chase Geiser explores the possibility that Luigi Mangione was a participant in a Stanford University study using psilocybin to treat chronic lower back pain. He notes that the lead researcher received funding from the Department of Defense for "team cohesion" studies, drawing parallels to historical MKUltra mind control experiments.
